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OBJECTIVES: To determine the proportion of published cost-
minimization analyses (CMAs) that provided appropriate evi-
dence of equivalence between drug comparators. METHODS:
Medline, Embase, and International Pharmaceutical Abstracts
(from inception to December 2006) were searched using the
words “cost” and “minimization”. Included articles were those
that: claimed to be a CMA, compared costs between drugs,
reported original research, and were available as full-text
(abstracts/reviews/letters were not accepted). Data extraction
was performed by two independent reviewers and included: evi-
dence of equivalence, journal type, publication date, and class of
drug. To determine adequacy of evidence of equivalence, each
article was assessed for source of data as well as strength of effec-
tiveness between comparators, and categorized as: “adequate”,
“questionable”, and “inadequate”. All differences in raters’ deci-
sions were resolved through consensus. RESULTS: A total of 67
articles were assessed for evidence of equivalence. Of those, the
majority were from the US/Canada, followed by Europe. Only
one article was from outside these regions (Australia). CMAs
were most published in general medicine journals and in the ﬁeld
of cardiovascular drugs. Of the total accepted studies, 9 (13.4%)
were judged “adequate”, 21 studies (31.3%) were categorized as
“questionable”, and 37 (55.2%) studies had “inadequate” evi-
dence of equivalence of comparators. The majority of studies
failed to prove their comparators’ equivalence because the evi-
dence in the literature supported different outcome results,
because some of these studies simply assumed equivalence, or did
not provide any evidence at all. No correlation was found
between studies that provided “adequate” or “inadequate”
equivalence and year of publication. CONCLUSION: The
majority of studies failed to provide adequate evidence of the
suitability of CMA as an analytic technique. Guidelines should
be developed that explicitly specify criteria for the performance
of a CMA in future studies.
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OBJECTIVES: The incremental cost-effectiveness ratio (ICER) 
is commonly calculated by health-economic researchers as a
method to communicate the relative incremental value among
treatments. It is intended as evidence to determine whether a
drug is a good value. However, as a single number presented as
a value in a local currency it is poorly understood by the average
health care decision maker(s). The objective of this project was
to re-examine the ICER value and design an economic calcula-
tion that would be more readily understood and more easily
interpretable by the customers of health economic information,
the health care decision makers. METHODS: The components
of the ICER were evaluated and rearranged in various possible
calculations to yield a value that was comparable across differ-
ent treatments utilizing the available cost (price) and effec-
tiveness components of medical treatments. RESULTS: The
incremental effectiveness per incremental cost ratio (IECR) or
“incremental value” is proposed. The incremental difference in
effectiveness is expressed as a ratio to the incremental difference
in cost, with all factors expressed in percentages. We compared
the traditional ICER to the proposed IECR. If a new treatment
had an IECR value of 100% it would be considered neutral. If
the IECR was less than 100% it could be considered needing
alternative value, and any value greater than 100% would gen-
erally be considered positive value. Examples: Drug-A : Drug-B
Cost $100 : $160. Effectiveness 50% : 80%. ICER : IECR $200 :
100% = EVEN. Cost $100 : $140. Effectiveness 50% : 80%
ICER : IECR $133 150% = GOOD. Cost $100 : $180. Effective-
ness 50% : 80%. ICER : IECR $267 : 75% = POOR. CONCLU-
SION: The results of the IECR calculation are easily
interpretable and produce a value that is simple to compare
across treatments. The IECR removes The oretical value of the
ICER, which is difﬁcult for decision makers to interpret, and
replaces it with a value that has an interpretable reference range.
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OBJECTIVES: Budget Impact Analysis (BIA) addresses the ques-
tion of whether a new drug is affordable by the health care
system in which it is being introduced. In Canada, committees
and managers of each public drug plan make reimbursement
decisions regarding new drugs. Most drug plan managers now
require economic data, including a BIA, as part of the formal
decision process on the pricing and reimbursement of drugs.
There is currently no standardized method of performing and
presenting BIAs for submission. METHODS: A survey of repre-
sentatives across Canada and a review of 35 previously submit-
ted BIAs were conducted to assess existing needs for BIA
guidelines. Based on these ﬁndings, previously published guide-
lines (ISPOR) and input from the project’s Steering Committee,
BIA guidelines were developed to provide detailed instruction on
how BIAs should be performed. An interactive budget impact
model template was designed to facilitate BIA model develop-
ment. RESULTS: Five key problem areas were identiﬁed for
improvement in BIA models: Lack of transparency, inaccurate or
misapplied assumptions, generalized analysis non-speciﬁc or
inaccurate to jurisdiction and/or plan, inappropriate choice of
comparators; and overall quality. The guidelines and accompa-
nying template address these problems and cover model design,
analytic perspective, time horizon, target population, costing,
scenarios to be compared, uncertainty analysis, discounting and
validation methods that should be used when preparing a BIA
as well as provide detailed guidance on data inputs and data
sources. CONCLUSION: The BIA guidelines and accompanying
template address the requirements of each of the participating
drug plans in Canada. Both have been endorsed by the National
Prescription Drug Utilization Information System (NPDUIS)
Steering Committee and the PMPRB for the standardization of
BIA submissions. The intended audience includes those who
develop, submit or use BIA models, and drug plan managers who
evaluate BIA submissions.
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OBJECTIVES: Any economic evaluation of a health care inter-
vention is only as good as the effectiveness data it is built upon
(Drummond 1997). Despite this knowledge, the quality of infor-
mation on clinical effectiveness is still poor. METHODS: The
main reason is that most data, at least on medicinal drugs, is tai-
lored towards obtaining a market authorisation. Competent
authorities, in the European Union, the United States and
